Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Recommendation of “Buy” from Analysts

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTXGet Rating) have earned a consensus recommendation of “Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $15.00.

A number of research firms have commented on VKTX. StockNews.com began coverage on Viking Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Raymond James decreased their target price on Viking Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, February 10th. Finally, Zacks Investment Research downgraded Viking Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 7th.

Shares of NASDAQ VKTX opened at $2.60 on Wednesday. Viking Therapeutics has a one year low of $2.54 and a one year high of $7.20. The firm has a market capitalization of $201.17 million, a P/E ratio of -3.61 and a beta of 1.67. The company’s fifty day moving average is $3.21 and its two-hundred day moving average is $4.42.

Viking Therapeutics (NASDAQ:VKTXGet Rating) last released its quarterly earnings data on Wednesday, February 9th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. During the same quarter in the previous year, the company posted ($0.15) EPS. As a group, equities research analysts forecast that Viking Therapeutics will post -0.86 earnings per share for the current year.

Large investors have recently modified their holdings of the company. Lindbrook Capital LLC lifted its position in shares of Viking Therapeutics by 1,062.8% in the fourth quarter. Lindbrook Capital LLC now owns 7,500 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 6,855 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of Viking Therapeutics in the fourth quarter valued at $38,000. Qube Research & Technologies Ltd acquired a new position in Viking Therapeutics in the fourth quarter valued at $51,000. Fox Run Management L.L.C. acquired a new position in Viking Therapeutics in the fourth quarter valued at $52,000. Finally, Virtu Financial LLC acquired a new position in Viking Therapeutics in the fourth quarter valued at $58,000. Institutional investors and hedge funds own 46.05% of the company’s stock.

Viking Therapeutics Company Profile (Get Rating)

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Recommended Stories

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.